Program
hafnium oxide
Also written as “JNJ-90301900”, “PEP503” and “JNJ-90301900 (NBTXR3)”.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 3 companies.
Drug pageHafnium oxide: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 33 open or running | phase 3since May 4, 2021 | May 4, 2021 | Jun 30, 2028phase 3 · NCT04892173 |
| PharmaEngineits history only | 20 open or running | phase 2since Jun 1, 2015 | Jun 1, 2015 | none ahead |
| Nanobiotix | 11 open or running | phase 1since Apr 10, 2018 | Apr 10, 2018 | Apr 30, 2027phase 1 · NCT03589339 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-1900 (NBTXR3)
, phase 3, as of Oct 13, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Nanobiotix only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2018First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT03589339 · 145 enrolled · United States
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT03589339
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Nanobiotix leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03589339Squamous Cell Carcinoma of Head and Neck · United States | 1 | Active, not recruiting | Apr 30, 2027 | 145 |
How it is read
Names in the registry
- “JNJ-90301900”, 2 entries
- “PEP503”, 2 entries
- “JNJ-90301900 (NBTXR3)”, 1 entry
- “NBTXR3”, 1 entry
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Rectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.